AMSBIO has introduced human recombinant iMatrix Laminin 211 fragment for the purification and maintenance of cardiomyocytes in culture.
The Laminin family of glycoproteins are an integral part of the structural scaffolding in almost every tissue of an organism. They are secreted and incorporated into cell-associated extracellular matrices. Laminin is vital for the maintenance and survival of tissues. Defective Laminins can cause muscles to form improperly, leading to a form of muscular dystrophy, lethal skin blistering disease and defects of the kidney filter.
News
Just as when you sell a house you need all your ducks in a row when you hit the market, so too is preparation equally crucial for a tech start up seeking funding. Anyone looking to grow their business should attend the workshop, which will be delivered by Simon Portman, a Solicitor at Marks & Clerk. The workshop will cover:
• Good housekeeping and risk management.
• Team dynamics
• Contracts and legal matters
• Intellectual property strategy
• Pitfalls to avoid
CAMBRIDGE, UK, 30 October 2019 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has moved to Coldham’s Business Park, Cambridge, UK. The new facility will enable the continued growth of the Company as it continues in its mission to develop a desktop DNA synthesis platform based on its proprietary silicon chip.
GiroNEX – a technology spin-out from Innomech Group – has today announced a move into the pharmaceutical manufacturing equipment market with the launch of its Cube Plus automated precision powder dispensing system for use in manufacturing powder-filled capsules and vials for early phase clinical trials and related drug development studies.
29 October 2019, Cambridge, UK - Sense Biodetection Limited (Sense) has today announced that it has raised £12.3m to develop its portfolio of instrument-free, point-of-care molecular diagnostic tests, a pioneering new class of diagnostic product.
The company has raised £10.5m Series A investment co-led by Cambridge Innovation Capital (CIC) and Earlybird, with participation from Jonathan Milner and seed round investor Mercia Asset Management. Concurrent with the investment, Sense has also secured a grant of £1.8m from Innovate UK.
Cambridge, UK, October 29 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine has joined 3TR, a large-scale public-private research initiative that aims to provide new insights into the mechanisms of response and non-response to treatment within and across seven different immune-mediated diseases.
Cambridge, UK, and Croissy-Beaubourg, France 28th October: PredictImmune, developers of pioneering prognostic tools for guiding treatment options in immune-mediated diseases, today confirmed that it has entered into a commercial partnership with Theradiag, a pioneering European diagnostic company specialising in in vitro diagnostics and theranostics for autoimmune diseases and the monitoring of biotherapies, specifically for IBD patients.
Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organization funding type 1 diabetes (T1D) research.
Cambridge, UK, October 22 2019: o2h discovery is pleased to announce a significant expansion in its existing Synthetic Chemistry collaboration with Sosei Heptares, an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and Structure-Based Drug Design platform capabilities.
Exclusive deal with KSL Biomedical signals PredictImmune’s major move into North America